Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Status:
Not yet recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in
patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy
in patients with stage II-IIIA NSCLC